Victory Medical Center Pharmacy, Austin, TX
Is Victory Medical Center Pharmacy registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Victory Medical Center Pharmacy hold a Texas pharmacy license?
The Texas State Board of Pharmacy lists license 34449 for VICTORY MEDICAL CENTER PHARMACY, AUSTIN, status Active, as of Nov 15, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 7130 for Victory Medical Center Pharmacy LLC, Austin, TX, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054022487 for VICTORY MEDICAL CENTER PHARMACY LLC, AUSTIN, TX, status ACTIVE and license 054022221 for VICTORY MEDICAL CENTER PHARMACY, AUSTIN, TX, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003218 for VICTORY MEDICAL CENTER PHARMACY, AUSTIN, TX, status INACTIVE (EXPIRED MORE THAN 3 YEARS - MUST REAPPLY), as of Nov 15, 2026.
Has Victory Medical Center Pharmacy had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Sep 10, 2026) for Victory Medical Center Pharmacy. State board actions: the Texas State Board of Pharmacy file dated Nov 15, 2026 does not mark prior disciplinary orders on license 34449.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Victory Medical Center Pharmacy
- Location
- Austin, TX
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Sep 10, 2026
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 11 observations
- State board records
- License found: 34449, Active
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Victory Medical Center Pharmacy, a 503A facility, with 1 dated action.
| Document | |||
|---|---|---|---|
| Sep 10, 2026 | Form 483 | 483 issued 09/10/2026 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 11 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 31, 2026 to Sep 10, 2026: 11 observations
- Firm on the cover
- Victory Medical Center Pharmacy, 4303 Victory Dr, Austin, TX 78704-7507
- FEI number
- 3010485868
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drug Products
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Use of ingredients not intended for pharmaceutical use in sterile drug production.
Specifically, the following was observed, but not limited to:
1) On August 31, 2026, the following dietary supplement grade APis were observed in your firm's raw material storage area and confirmed to be in use for sterile drug product production: Each API is labeled as dietary supplement grade. On August 31, 2026, your firm was directly observed using the above-referenced dietary supplement grade APis to aseptically produce ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML) **STOCK SOLUTION**, Lot 2055939, BUD October 20, 2026.
• :(t>) (4) I, USP, Lot[(6) (4) ] Expiration Date[(6) (4) • <Redacted B4>, Lot <Redacted B4>, Expiration Date <Redacted B4> • <Redacted B4>, Lot <Redacted B4>Expiration Date <Redacted B4> On August 31, 2026, the following dietary supplement grade APis were observed in your firm's raw material storage area and confirmed to be in use for sterile drug product production: Each API is labeled as dietary supplement grade. ...
Observation 2
Production areas have difficult to clean or contain porous, particle generating, or visibly dirty equipment or surfaces.
Specifically, on August 31, 2026, the following deficiencies were observed on your firm's <Redacted B4> ISO 5 <Redacted B4> Laminar Airflow Hood: Caulking material was observed applied along the frame edges ofthe HEPA filter housing within your firm's <Redacted B4> ISO 5 <Redacted B4> Laminar Airflow Hood (LAFH). The caulking exhibited the following defects:
[(6) (4) I Laminar Airflow Hood: Caulking material was observed applied along the frame edges ofthe HEPA filter housing within your finn's [(l5) (4) JISO 5[(15) (4) I Laminar Airflow Hood (LAFH). The caulking exhibited the following defects:
• Uneven and irregular application -The caulking was applied unevenly along the frame seams, resulting in inconsistent thickness and width, with visible ridges, valleys, and surface irregularities. These surface irregularities cannot be adequately cleaned or disinfected and provide sites where microbial contamination, cleaning solution residue, and particulate matter can accumulate and persist despite cleaning efforts. ...
Observation 3
Personnel were observed manually contacting the inner surface of a sterile container or closure.
Specifically, the following observations were made:
1) During the aseptic production on August 31, 2026 of ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML) **STOCK SOLUTION**, Lot 2055939, BUD October 20, 2026, the following aseptic processing techniques were directly observed:
• Your firm's sterile technician was observed reaching into a bag of rubber stoppers with a gloved hand to retrieve individual stoppers for placement onto vials. During this retrieval, the sterile technician was observed directly touching the inner surface (product contact area) of the rubber stoppers with their gloved hand.
• Your firm's sterile technician was observed pouring rubber stoppers directly from the bag onto the surface of the work bench and then using a gloved hand to retrieve individual stoppers from the bench surface for placement onto vials. ...
Observation 4
The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.
Specifically,
• Your firm's <Redacted B4> ISO 5 <Redacted B4> Laminar Airflow Hood (LAFH) is designed in a manner that potentially exposes sterile drug products and sterile containers/closures to air of a lower than ISO 5 classification. For example, I observed an air intake vent is located directly behind the sterile technician's working area inside of the ISO 5 LAFH. This vent has not been monitored for unidirectional airflow and is not included in your firm's <Redacted B4> environmental monitoring sampling program. On August 31, 2026, I observed open and exposed vials of ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML), Lot 2055939, waiting to be stopper, and exposed rubber stoppers directly in front of the air intake vent.
• I observed that your firm's: <Redacted B4> connecting the unclassified space to the ISO 8 buffer room lacks a HEPA filter. This design allows unfiltered, lower-quality air from the unclassified space to enter the ISO 8 ante room.
Observation 5
The <Redacted B4> intended to render final product sterile is not adequate and not appropriate for pharmaceutical use.
Specifically, your firm uses the <Redacted B4> Ref <Redacted B4> as its sterilizing <Redacted B4> for final product <Redacted B4>. According to the manufacturer's specifications, this <Redacted B4> has a recommended maximum <Redacted B4> volume of <Redacted B4>. The following examples demonstrate your firm's failure to adhere to this specification:
• SEMAGLUTIDE/L-CARNITINE (5/50MG/ML) **STOCK SOLUTION**, Lot 2059406, BUD November 2, 2026 -On September 3, 2026, I observed your firm's personnel using a <Redacted B4> to aseptically <Redacted B4> of solution, exceeding the manufacturer's recommended maximum <Redacted B4> volume of <Redacted B4>.
• ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML) **STOCK SOLUTION**, Lot 2026504, BUD October 15, 2026-Your firm's batch record documents the <Redacted B4> of <Redacted B4> of solution; however, no sterilizing <Redacted B4> is documented in the batch record for this lot. ...
Observation 6
Failure to conduct post-use <Redacted B4> testing on <Redacted B4> used to sterilize drug products.
Specifically, but not limited to, the following examples were observed:
• ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BI CARBONATE (105MG/28MG/B-COMPLEX, 12MG/ML) * *STOCK SOLUTION**, Lot 2026504, BUD October 15, 2026, Qty <Redacted B4>. No documented <Redacted B4> test was found in the batch record for this lot. ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX, 12MG/ML) * *STOCK SOLUTION**, Lot 2026504, BUD October 15, 2026, was used to fill <Redacted B4> 9ml vials of ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML), Lot 2027642, BUD October 15, 2026 <Redacted B4> vials were dispensed on <Redacted B4>
• ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML) **STOCK SOLUTION**, Lot 2055939, BUD October 20, 2026, Qty <Reda cted B 4>. ...
Observation 7
Failure to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.
Specifically, the following deficiencies were observed:
• The sterile technician failed to clean the sides and back surfaces ofthe:(15) (4) I located inside ofthe ISO 5 LAFH. • The sterile technician failed to clean in between the grates of the vent located <Redacted B4> the <Redacted B4>
These deficiencies were observed on the following occasions:
Between production of TIRZEPATIDE/L-CARNITINE (25/50 MG/ML) STOCK SOLUTION, Lot 2057051 , and ZINC SULFATE (MDV) 10 MG/ML STOCK SOLUTION, Lot 2057427, on September 1, 2026; end of day cleaning on September 1, 2026; and end of day cleaning on September 3, 2026.
Observation 8
Lack of routine environmental monitoring in the ISO 5 area and classified areas.
Specifically, the following deficiencies were observed:
1) Absence of Historical Surface Sampling Data -Your firm was unable to provide surfac e sampling environmental monitoring data for your ISO 5 Laminar Airflow Hood (LAFH) an d classified cleanrooms prior to July 29, 2026 . Despite this absence of surface sampling data, between June 5, 2026 and July 28, 2026, you r firm produced <Redacted B4> different sterile stock drug solutions intended to be filled into vial s or syringes and distributed to patients. For example, on July 27, 2026, your firm produced <Redacted B4> of ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BI CARBONATE (105MG/28MG/B-COMPLEX,12MG/ML) **STOCK SOLUTION**, Lot 2026504, BUD October 15, 2026, and filled <Redacted B4> 50 mL vials of ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML), Lot 2027642, BUD October 15, 2026. Of those <Redacted B4> vials, <Redacted B4> vials were dispensed to patients on <Redacted B4> . ...
Observation 9
Sterile drugs and Materials were exposed to lower than ISO 5 quality air.
Specifically, sterile wipes used to disinfect your firm's <Redacted B4> ISO 5 <Redacted B4> Laminar Airflow Hood (LAFH) were staged open and exposed to lower than ISO 5 quality air prior to use. On August 31, 2026, sterile wipes were observed staged open and exposed on a <Redacted B4> located in the ISO 7 cleanroom. These wipes were subsequently used to disinfect the firm's <Redacted B4> ISO 5 <Redacted B4> LAFH. According to firm personnel, sterile wipes are regularly removed from their packaging and stored open in the ISO 7 cleanroom prior to being used to disinfect the ISO 5 LAFH.
Observation 10
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically, the following deficiencies were observed:
• Media Fill Volume Does Not Represent Worst-Case Production Conditions -According to your firm's media fill records, your first <Redacted B4> of solution and fill <Redacted B4> control vials during media fills. However, your firm's personnel stated that the largest batch size in actual production is <Redacted B4> syringes. On August 31, 2026, I observed personnel asepticany <Redacted B4> of ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML), Lot 2056424 and fill U>l <4J_50ml vials of ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML), Lot 2056424 during routine operations.
• Media Fill Container Type Does Not Represent Current Practice -Your firm's media fills are conducted by filling vials only; however, your firm's personnel stated that actual production includes filling syringes, with the largest batch size of <Redacted B4> syringes. ...
Observation 11
Smoke studies were not performed under dynamic conditions.
Specifically, your firm failed to perform airflow visualization (smoke study) testing under dynamic operating conditions for your <Redacted B4> ISO 5 <Redacted B4> Laminar Airflow Hood (LAFH), which is used for the preparation of sterile drug products. No smoke study videos or written protocols exist demonstrating that airflow visualization testing had been performed under dynamic conditions in the ISO 5 LAFH.
Your recertifying company reported that a smoke study was performed April 14, 2026; however, your firm's personnel stated they had no knowledge of smoke studies ever having been performed in the ISO 5 LAFH.
State board of pharmacy records
The Texas State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status | Prior disciplinary orders (file flag) |
|---|---|---|---|---|---|
| 34449 | Community Sterile Compounding | VICTORY MEDICAL CENTER PHARMACY | AUSTIN | Active | No |
What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 7130 | OSP | Victory Medical Center Pharmacy LLC | Austin, TX | Active |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054022487 | LICENSED PHARMACY | VICTORY MEDICAL CENTER PHARMACY LLC | AUSTIN, TX | ACTIVE |
| 054022221 | LICENSED PHARMACY | VICTORY MEDICAL CENTER PHARMACY | AUSTIN, TX | CHANGE OF OWNERSHIP |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0003218 | NONRESIDENT PHARMACY | VICTORY MEDICAL CENTER PHARMACY | AUSTIN, TX | INACTIVE (EXPIRED MORE THAN 3 YEARS - MUST REAPPLY) |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Texas State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Texas State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.